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Colorectal cancer results from the malignant transformation of colonic epithelial cells. Stromal fibroblasts are the main com-
ponent of the tumour microenvironment, and play an important role in the progression of this and other neoplasias. Wnt/b-
catenin signalling is essential for colon homeostasis, but aberrant, constitutive activation of this pathway is a hallmark of
colorectal cancer. Here we present the first transcriptomic study on the effect of a Wnt factor on human colonic myofibro-
blasts. Wnt3A regulates the expression of 1,136 genes, of which 662 are upregulated and 474 are downregulated in CCD-
18Co cells. A set of genes encoding inhibitors of the Wnt/b-catenin pathway stand out among those induced by Wnt3A, which
suggests that there is a feedback inhibitory mechanism. We also show that the PKP2 gene encoding the desmosomal protein
Plakophilin-2 is a novel direct transcriptional target of Wnt/b-catenin in normal and colon cancer-associated fibroblasts. PKP2
is induced by b-catenin/TCF through three binding sites in the gene promoter and one additional binding site located in an
enhancer 20 kb upstream from the transcription start site. Moreover, Plakophilin-2 antagonizes Wnt/b-catenin transcriptional
activity in HEK-293T cells, which suggests that it may act as an intracellular inhibitor of the Wnt/b-catenin pathway. Our
results demonstrate that stromal fibroblasts respond to canonical Wnt signalling and that Plakophilin-2 plays a role in the
feedback control of this effect suggesting that the response to Wnt factors in the stroma may modulate Wnt activity in the
tumour cells.
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Colorectal cancer (CRC) is one of the leading causes of
cancer-related death in Western countries.1,2 CRC results from
the malignant transformation of epithelial cells lining the lumi-
nal surface of the colonic crypt, a process driven by cumulative
mutations in both oncogenes and tumour suppressor genes.3,4
Aberrant activation of the Wnt/b-catenin pathway is a hall-
mark of colorectal carcinoma and plays a key role in initiation
and progression of the tumour.5 Nevertheless, it is now well-
accepted that the surrounding tumour stroma plays an essen-
tial role in CRC progression.6–9 Therefore, understanding the
reciprocal interaction between colon carcinoma cells and
cancer-associated ﬁbroblasts (CAF) and other cell types in the
tumour stroma is of key importance in the design of new,
more efﬁcient strategies against this neoplasia.
Tumour stroma is composed of extracellular matrix
(ECM) proteins and a variety of cell types including endothe-
lial cells, pericytes, inﬁltrating immune cells, adipocytes and
CAF. A recent collaborative study has classiﬁed CRC into
four consensus molecular subtypes (CMS). CMS4, the type
with the worst prognosis, is characterized by strong trans-
forming growth factor (TGF)-b activation and high stromal
component.8 Another study has revealed that the CMS4 sub-
type displays high expression of immune signatures with
overexpression of markers of lymphocytes and cells of mono-
cytic origin with strong angiogenic and inﬂammatory compo-
nents.9 Moreover, most genes upregulated by TGF-b in
stem-like/mesenchymal, poor prognosis CRC are expressed
by stromal cells: CAF, leukocytes or endothelial cells.10,11
These data highlight the relevance of tumour stroma for
CRC progression.
Pericryptal ﬁbroblasts (PCF) in healthy colon stroma
secrete a variety of molecules, including Wnt factors, that
modulate adjacent epithelial cell growth and differentiation.7
Secreted Wnt ligands bind their receptors located at the
plasma membrane of stem cells and proliferative progenitors
at the bottom of the colon crypt, and trigger a signalling cas-
cade that regulates gene expression in the nucleus. The main
effector of this pathway is b-catenin. Wnt binding to Frizzled
and low density lipoprotein (LDL) receptor-related protein
(LRP) 5/6 receptor heterodimers leads to phosphorylation of
the cytoplasmic tail of LRP and to subsequent inhibition of a
multiprotein complex that is responsible for b-catenin degra-
dation.5 The tumour suppressors and scaffold proteins APC
(encoded by the adenomatous polyposis coli gene) and Axin,
as well as the kinases Casein Kinase 1 (CK1) and Glycogen
Synthase Kinase 3b (GSK3b) are the main components of
this b-catenin destruction complex. In the absence of Wnt
ligands, CK1 and GSK3b catalyse b-catenin N-terminal
phosphorylation which triggers b-catenin ubiquitination and
subsequent degradation by the proteasome. Inhibition of the b-
catenin destruction complex in response to Wnt signalling
results in b-catenin accumulation in the cytoplasm and its
translocation into the nucleus, where it behaves as a transcrip-
tional co-activator for LEF/TCF transcription factors. The LEF/
TCF family is composed of four members (TCF-1 to 24) that
bind to b-catenin/TCF binding sites in promoters and
enhancers of target genes and regulate their expression.5 Aber-
rant activation of the Wnt/b-catenin pathway is thought to be
the initial event and a driving force of colorectal tumorigenesis,
and most human CRC carry mutations in genes that encode
intracellular members of this pathway (including APC,
CTNNB1/b-catenin and AXIN1/2 genes).5
In spite of the abundant literature on Wnt/b-catenin sig-
nalling in CRC and colon epithelial cells, studies are lacking
on how Wnt signalling affects colon PCF. It is highly likely
that Wnt factors secreted by PCF and possibly other crypt
cell types bind not only Wnt receptors in crypt epithelial
cells, but also those in PCF themselves, triggering a Wnt sig-
nalling cascade. Therefore, we studied the transcriptomic
response to Wnt3A in established human normal colonic
myoﬁbroblasts (CCD-18Co). To our knowledge, this is the
ﬁrst study that explores the transcriptomic effect of Wnt pro-
teins on human colon myoﬁbroblasts. Our analysis rendered
a total of 1,136 regulated genes, of which 662 were upregu-
lated and 474 were downregulated. The gene encoding the
desmosomal protein Plakophilin-2 (PKP2) was upregulated
by Wnt3A in CCD-18Co as well as in primary cultures of
normal ﬁbroblasts (NF) and CAF derived from CRC patients.
Like b-catenin, plakophilins are members of the armadillo
family that are located both in the cytoplasm and in the
nucleus.12 Here we show that PKP2 is a b-catenin/TCF target
gene whose expression is regulated through several b-cate-
nin/TCF binding sites present in its promoter and in an
enhancer sequence located 20 kb upstream from its transcrip-
tion start site (TSS). Moreover, our data suggest that
Plakophilin-2 may act as an antagonist of b-catenin/TCF
complexes on Wnt-activated promoters.
Material and Methods
Cells and cell culture
CCD-18Co (ATCC CRL-1459) human colon myoﬁbroblasts
were purchased from the ATCC and cultured in Minimum
What’s new?
Cancer-associated fibroblasts in the tumour microenvironment play a critical role in colorectal cancer (CRC) progression. In
this transcriptomic study of human colon fibroblasts, profound changes in fibroblast gene expression profile were linked to
Wnt3A signalling. Wnt3A signalling was associated particularly with the induction of inhibitors of the Wnt/b-catenin pathway,
indicative of an inhibitory feedback mechanism. Among the genes most strongly upregulated was PKP2, a novel transcriptional
target of Wnt/b-catenin signalling in both normal and colon cancer-associated fibroblasts. Plakophilin-2 protein, previously
known to be widely expressed in carcinomas, was further found to antagonize Wnt/b-catenin transcriptional activity.
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Essential Medium (MEM, Life Technologies, Carlsbad, CA).
IMR-90 ﬁbroblasts (ATCC CCL-186), human embryonic kid-
ney (HEK)-293T cells, HeLa cells, and MCF7 breast cancer
cells were cultured in Dulbecco’s modiﬁed Eagle’s medium
(DMEM, Life Technologies). All media were supplemented
with 10% Foetal Bovine Serum (FBS, Life Technologies) and
MEM also with L-glutamine and sodium pyruvate (both from
Life Technologies). Cell lines were periodically authenticated
with the GenePrint 10 System (Promega, Fitchburg, WI) and
the results were sent for comparison against the ATCC cell
line database (Manassas, VA). Cells were treated with 200
mg/ml recombinant human Wnt3A (rhWnt3A, R&D Systems,
Minneapolis, MN) in 0.1% phosphate buffer saline–bovine
serum albumin (PBS-BSA) to a ﬁnal concentration of 100
ng/ml, or with the corresponding vehicle (PBS-BSA)
concentration.
Primary cultures of human colon NF and CAF were
obtained following the explant outgrowth technique13,14 from
fresh surgical specimens of colon primary tumour and mor-
phologically normal colonic mucosa (at least 5 cm from the
surgical margin) of the same patient resected from CRC
patients subjected to surgery at the Hospital Universitario La
Paz (Madrid, Spain). Samples were provided by the IdiPAZ
Biobank (PT13/0010/0003: Plataforma de Apoyo a la Inves-
tigacion en Ciencias y Tecnologıas de la Salud en la Red de
Biobancos 2013), integrated into the Spanish Biobank Net-
work (www.redbiobancos.es). Brieﬂy, tissue samples were
incubated for 30 min with PBS containing 0.5 mg/ml Primo-
cin (Invivogen, San Diego, CA), 0.1 mg/ml gentamicin and
0.5 mg/ml amphotericin-B (both from Life Technologies).
Then, tissue samples were cut into small pieces of approxi-
mately 3 mm3 in size and seeded in cell culture ﬂasks in FBS
with 0.25 mg/ml Primocin. After 1 week and to facilitate
ﬁbroblast growth, FBS was replaced by Fibroblast Growth
Medium-2 (FGM-2, Lonza, Basel, Switzerland). Fibroblasts
grew around the explants for approximately 3 weeks. Then,
tissue fragments were removed and ﬁbroblasts were routinely
subcultured at 1:2 ratio in FGM-2. Experiments were per-
formed with primary ﬁbroblasts at the seventh passage at
most. This study was approved by the Ethics Committee for
Clinical Research of the Hospital Universitario La Paz
(HULP-PI-1425), and all patients gave written informed
consent.
RNA sequencing and analysis of gene expression
CCD-18Co cells were stimulated with rhWnt3A or vehicle,
and three biological replicates per sample were collected and
sequenced on the Illumina HiSeq 2000 platform (Spanish
National Cancer Research Centre, CNIO). Image analysis,
per-cycle basecalling and quality score assignment was per-
formed with Illumina Real-Time Analysis software. The Illu-
mina2bam tool (Wellcome Trust Sanger Institute—NPG) was
used to convert BCL ﬁles to bam format. To align fastq
reads, we employed TopHat15 version 2.0.14 against hg19/
GRCh37.75 assembly of the human reference genome,16
using standard parameters. Feature alignments were quanti-
ﬁed using HTSeq-counts from HTSeq framework version
0.6.0,17 using the GRCh37.75 GTF gene model. We used the
edgeR package version 3.12.118 for R statistical computing
software to normalize the count data, and statistical analysis
to identify differentially expressed genes.
RNA isolation and RT-qPCR
Total RNA was extracted from cells with the RNeasy mini kit
(Qiagen, Hilden, Germany). Complementary DNA was syn-
thesized from 0.5 lg of total RNA using the ImProm-II
Reverse Transcription System (Promega). Then, the qPCR
reaction was performed in a CFX384 Real-Time PCR Detec-
tion System (Bio-Rad, Hercules, CA), using TaqMan Univer-
sal Master Mix II without UNG (Applied Biosystems, Foster
City, CA). Thermal cycling of the qPCR reaction was initi-
ated with a denaturation step at 958C for 10 min, and con-
sisted of 40 cycles (denaturation at 958C 15 sec, annealing
and elongation at 608C for 30 sec). We used TaqMan probes
for PKP2 (Hs00428040_m1), PTGER3 (Hs00168755_m1),
APCDD1 (Hs00537787_m1), DKK2 (Hs00205294_m1),
NKD1 (Hs00263894_m1), NKD2 (Hs01108239_m1), WNT16
(Hs00365138_m1), TRPA1 (Hs00175798_m1), ODZ3 (Hs0
1111780_m1), ILDR2 (Hs01025498_m1), AMIGO2 (Hs00
827141_g1), PKP1 (Hs00240873_m1), PKP3 (Hs00170
887_m1), PKP4 (Hs00269305_m1), VIM (Hs00958111_m1)
and ACTA2 (Hs00426835_g1) (Applied Biosystems). The
expression levels were normalized to the levels of human
ribosomal protein RPLPO (Taqman probe set 4310879E). All
experiments were performed in triplicate.
Western blotting
Whole-cell extracts were prepared by cell lysis with RIPA
buffer plus protease- and phosphatase-inhibitors for 20 min
on ice, followed by centrifugation at 13,200 rpm for 15 min
at 48C. Proteins were separated by SDS-PAGE, transferred to
PVDF membranes and incubated with antibodies against
Plakophilin-2 (sc-136039, Santa Cruz Biotechnology, Santa
Cruz, CA; 651101, Progen, Heidelberg, Germany), b-catenin
(610154, BD Transduction Laboratories, San Jose, CA),
GSK3b (610201, BD Transduction laboratories), Vimentin
(M7020, clone V9, Dako), a-SMA (A5228, clone 1A4, Sigma-
Aldrich), GAPDH (G9545, Sigma-Aldrich) and b-actin (sc-
1616, Santa Cruz Biotechnology), and then with HRP-
conjugated secondary antibodies. Antibody binding was visu-
alized using the ECL detection system (GE Healthcare, Chal-
font St. Gills, UK). Films were scanned with a HP Scanjet
G2710 (Palo Alto, CA) and images were processed using
Adobe Photoshop CS6 (San Jose, CA). Quantiﬁcation was
done by densitometry, using ImageJ (National Institutes of
Health, Bethesda, MD).
PKP2 promoter and enhancer constructs
Genomic DNA, obtained from CCD-18Co human normal
colon myoﬁbroblasts, was used to amplify by PCR two
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upstream sequences of the PKP2 promoter. PCR was per-
formed using the Certamp Kit for complex ampliﬁcations
(Biotools, Madrid, Spain) and primers 50-CATCTCAGCATC
ATGGTTGG-30 and 50-GAGAAACTCCAACAAGAGGC-30
for the 21509/–735 fragment, containing the putative b-cate-
nin/TCF binding sites, and 50-TTAATCAACGTTAGC
AGGGC-30 and 50-ACAGGATGGATTTCCGCTCG-30 for
the control 2817/–299 fragment. The resulting PCR products
were cloned into the pGEM-T Easy vector (Promega) and
sequenced. Subsequently, a second PCR was performed to
generate suitable restriction sites using primers:
50-TTGGTACCTTCTATTGGGGTGGGAGC-30 and 50-
ATAAAGCTTGAGAAACTCCAACAAGAGGC-30 for the
21509/–735 fragment, and 50- ATGGTACCTTAATCAA
CGTTAGCAGGGC-30 and 50-TACAAGCTTACAGGATGGA
TTTCCGCTCG-30 for the 2817/–299 fragment. The PCR
products were digested with KpnI and HindIII (New England
Biolabs, Ipswich, MA), cloned into the pGL4.23 luciferase
reporter plasmid (Promega) and sequenced. Site-directed
mutagenesis of b-catenin/TCF binding sites on the
21509/–735 PKP2 promoter construct was performed using
the Agilent QuikChange II XL Site-Directed Mutagenesis Kit
(Agilent Technologies, Santa Clara, CA), and the wild-type
50-CCTTTG(A/T)(A/T)-30 sites were changed into
50-CCTTTGGC-30. Primers used for the seven single-site
mutations are shown in Supporting Information Table I. The
triple mutant 21509/–735-m347 construct was generated by
three rounds of mutation on the wild-type construct. All con-
structs were sequenced.
The 220666/–20091 PKP2 enhancer region was ampliﬁed
by PCR using the same template and kit as above, and pri-
mers 50-CGGTTTTACTCAAGTAAGC-30 and 50-
GCAATCTTCTTGATGAGTAG-30. The resulting PCR prod-
uct was cloned into the pGEM-T Easy vector and sequenced.
A second PCR was performed to generate KpnI restriction
sites using primers: 50-TTGGTACCCGGTTTTACTCAA
GTAAGC-30 and 50-ATGGTACCGCAATCTTCTTGATGA
GTAG-30. The PCR product was digested with KpnI and
cloned into the pGL4.23 luciferase reporter plasmid. Con-
structs harbouring the PKP2 enhancer in both forward
(–20666/–20091) and reverse (–20091/–20666) orientations
were selected and sequenced. Site-directed mutagenesis of
b-catenin/TCF binding sites on the 220091/–20666 PKP2
enhancer construct was performed as above and the primers
used for each single-site mutation are shown in Supporting
Information Table I.
Transfections, plasmids and reporter assays
Subconﬂuent cells cultures were transfected in triplicate using
the jetPEI transfection reagent (PolyPlus Transfection, Ill-
kirch, France), following the manufacturer’s guidelines. The
reporter plasmids pTOPFLASH, pFOPFLASH, 4xwtCBF1Luc,
4xmtCBF1Luc, NF3, and that harbouring the 22235/1112
region of the DKK1 promoter upstream of the Fireﬂy lucifer-
ase gene have been previously described.19–22 The reporter
plasmids harbouring wild-type and mutant PKP2 promoter
and enhancer sequences are described above. The expression
plasmid pFLAG-CMV.5.1-Plakophilin2a-ﬂag encoding
Plakophilin-2 was purchased from Addgene (Cambridge,
MA). The expression plasmids pMT23-b-catenin, pCDNA3-
TCF4-VP16 and pCDNA3-p65 have been described else-
where.22–24 The expression plasmid pCDNA3-ICND was a
generous gift from Keith R. Brennan (University of Manches-
ter, UK). A Renilla luciferase plasmid (pRL-TK) was used in
all experiments as an internal control. Fireﬂy and Renilla
luciferase activities were measured separately using the Dual
Luciferase reagent kit (Promega) and a GloMax 96 micro-
plate luminometer (Promega).
Statistical analysis
The signiﬁcance of differences between two groups was
assessed by the Student’s t test. The differences between more
than two group means were analysed with ANOVA, and
considered statistically signiﬁcant when the reported p values
were below 0.05. A Tukey post-hoc test was applied after a
signiﬁcant ANOVA to compare differences between pairs of
groups.
Results
Analysis of Wnt3A transcriptome in CCD-18Co human
colon myofibroblasts
To investigate the effect of Wnt signalling on human colon
myoﬁbroblasts, we studied the transcriptional response of
this cell type to Wnt3A stimulation. For this purpose, we
selected the colon subepithelial myoﬁbroblast cell line CCD-
18Co25 as a model system. CCD-18Co cells express Frizzled
receptors 1 through 7 (Supporting Information Fig. S1A; data
not shown) and respond to Wnt3A treatment with a substan-
tial increase in cytoplasmic levels of b-catenin (Supporting
Information Fig. S1B and C). We performed RNA sequenc-
ing on three independent biological replicates of CCD-18Co
cells treated with either Wnt3A (100 ng/ml) or vehicle for 24
hr, as described in the Material and Methods section. An
analysis of the data rendered a total of 1,136 differentially
expressed genes (FDR< 0.05), of which 662 were upregulated
and 474 were downregulated in response to Wnt3A (Sup-
porting Information Tables II and III). These genes were
involved in a wide variety of cellular functions. The complete
list of genes was deposited in the GEO database (accession
no. GSE89124). To validate our analysis, we selected some of
the upregulated (PTGER3, ODZ3, ILDR2 and AMIGO2) and
downregulated (WNT16, TRPA1) genes in our study and per-
formed RT-qPCR on a new set of RNA samples. All these
genes were conﬁrmed as being regulated by Wnt3A (Fig. 1a).
In support of our study, a gene set enrichment analysis
(GSEA) showed that the hallmark gene set that most closely
correlated with our list of genes regulated by Wnt3A in
CCD-18Co cells was that of genes upregulated by activation
of Wnt signalling through accumulation of CTNNB1/b-cate-
nin (FDR q-val5 0.001; FWER p-val5 0.001). Interestingly,
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the GSEA analysis showed a signiﬁcant inverse correlation
between our list of genes and genes deﬁning epithelial-
mesenchymal transition (EMT), as in wound healing, ﬁbrosis
and metastasis (FDR q-val5 0.022; FWER p-val5 0.019).
Consequently, genes upregulated in EMT appear to be down-
regulated by Wnt3A in colon myoﬁbroblasts. In contrast,
activation of the Wnt/b-catenin pathway is known to pro-
mote EMT in epithelial cancer cells.26 Therefore, some
Figure 1. Wnt3A regulates the expression of multiple genes in CCD-18Co human colon myofibroblasts. (a) Validation using RT-qPCR of a
representative sample of six genes (PTGER3, ODZ3, ILDR2, AMIGO2, WNT16 and TRPA1) that were up- or downregulated by Wnt3A in RNA-
seq experiments. Cells were treated with either Wnt3A (1) or vehicle (–) for 24 hr. The results shown are means6S.D. of three indepen-
dent biological samples, each one determined in triplicate (***p0.001). (b) Wnt3A triggers the expression of a set of target genes encod-
ing inhibitors of the Wnt/b-catenin pathway. Cells were stimulated with either Wnt3A or vehicle for the indicated times and NKD1, NKD2,
DKK2, and APCDD1 expression was analysed by RT-qPCR. Results are shown as fold over control at the indicated times and are means6
S.D. of three independent biological samples, each one determined in triplicate (n.s., non-significant; *** p0.001).
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genetic programs induced by Wnt3A in myoﬁbroblasts differ
from those induced in other cell types. This conﬁrms previ-
ous knowledge that Wnt target genes are cell-type speciﬁc. In
agreement, a list of genes upregulated by the EWS-FLI1
oncogenic fusion protein in Ewing’s sarcoma cells showed a
direct correlation with genes upregulated by Wnt3A in CCD-
18Co cells (FDR q-val< 0.001; FWER p-val< 0.001),
although we and others have demonstrated mutual antago-
nism between EWS-FLI1 and Wnt/b-catenin signalling in
Ewing’s sarcoma23,27 (Supporting Information Fig. S2).
Wnt3A induces the expression of Wnt inhibitors in human
fibroblasts
Among the genes upregulated by Wnt3A in CCD-18Co cells,
we detected a set that encodes Wnt/b-catenin pathway inhib-
itors, such as the extracellular antagonist Dickkopf-2 (DKK2),
the membrane-bound inhibitor Adenomatous Polyposis Coli
Downregulated 1 protein (APCDD1), and the cytoplasmic
inhibitors Naked-1 (NKD1), Naked-2 (NKD2), and Axin 2
(AXIN2). Time-course experiments conﬁrmed that DKK2 was
already upregulated 4 hr after treatment with Wnt3A, while
NKD1, NKD2 and APCDD1 exhibited signiﬁcant increases at
8 hr post-treatment (Fig. 1b). All these genes were also upre-
gulated by Wnt3A in IMR-90 human lung ﬁbroblasts, which
suggests that they may be common Wnt3A targets in ﬁbro-
blasts (Supporting Information Fig. S3). Altogether, these
data suggest that Wnt3A induces the expression of a variety
of Wnt inhibitors that, in turn, may be responsible for feed-
back inhibition of the pathway in ﬁbroblasts.
Wnt3A induces PKP2 expression in normal and colon
cancer-associated fibroblasts
For a detailed study, we chose the PKP2 gene, which is con-
sistently upregulated by Wnt3A in CCD-18Co cells and enco-
des the protein Plakophilin-2, whose effect on Wnt signalling
and relation to cancer is controversial (see the Discussion
section). Plakophilin-2 belongs to the armadillo-repeat pro-
tein family, along with b-catenin, plakoglobin, p120-catenin,
and other plakophilins. The PKP2 mRNA level augmented 4-
fold in response to Wnt3A (Fig. 2a), which led to a 2-fold
increase in protein level 24 hr after treatment (Fig. 2b). This
was due to activation of the Wnt/b-catenin signalling path-
way, since pre-treatment with the pathway inhibitor XAV-
939 impaired Plakophilin-2 accumulation (Fig. 2c). Moreover,
Wnt5A, a noncanonical Wnt that cannot trigger b-catenin-
induced signalling, could not upregulate PKP2 expression
(Fig. 2d). Other PKP subfamily members, including PKP3
and PKP4/p0071, were not regulated by Wnt3A in CCD-
18Co cells, which suggests that the effect on PKP2 is speciﬁc
(Fig. 2e).
To address whether PKP2 upregulation by Wnt3A also
takes place in primary colonic ﬁbroblasts we established pri-
mary cultures of NF and CAF from fresh tumour tissue, and
paired adjacent normal colon mucosa obtained from biopsies
of CRC patients using the explant outgrowth technique.13,14
Both NF and CAF are vimentin and a-SMA positive, and the
expression of a-SMA is frequently higher in CAF than in
their paired NF, indicating a more myoﬁbroblastic phenotype
of CAF (Supporting Information Fig. S4A and B). Wnt3A
consistently increased the expression of PKP2 in both CAF
and NF, although with differences among patients (Fig. 3a
and b).
Wnt3A induces PKP2 gene transcription through b-catenin/
TCF binding sites
To get further insight into the mechanism of PKP2 gene reg-
ulation by Wnt3A, we treated CCD-18Co cells with actino-
mycin D (ACTD), an inhibitor of transcription, before
stimulation with Wnt3A. ACTD completely blocked the
upregulation of PKP2 triggered by Wnt3A (Fig. 4a), which
argues in favour of a transcriptional mechanism.
We next made use of the UCSC Genome Browser28 and
data from the ENCODE Project29 to study the regulatory
regions of the human PKP2 gene. Available ChIP-seq data
for transcription factor TCF-4 (TCF7L2 gene) in different cell
types suggested two putative binding regions for this factor: a
promoter region around the transcription start site (TSS) of
the human PKP2 gene, and an enhancer region located about
20 kb upstream from the TSS (Supporting Information Fig.
S5A). In silico analysis of both regions revealed up to 7 puta-
tive b-catenin/TCF binding sites in the promoter (Supporting
Information Fig. S5B) and up to 3 putative b-catenin/TCF
binding sites in the enhancer (Supporting Information Fig.
S5C).
We PCR-ampliﬁed and cloned both relevant sequences
into the pGL4.23 plasmid upstream from the luciferase
reporter gene and a minimal promoter (Figs. 4b and 5a). The
transcriptional activity of the 21509/–735 PKP2 promoter
construct containing all 7 putative b-catenin/TCF binding
sites was consistently stimulated by TCF4-VP16, a constitu-
tively active version of TCF-4, in HEK-293T, HeLa and
MCF7 cells (Fig. 4c and Supporting Information Fig. S6). Its
induction was comparable to that of the DKK1 gene pro-
moter, a well-known b-catenin/TCF target gene22,30,31 (Fig.
4c). In contrast, a construct containing the 2817/–299 pro-
moter region that does not contain any putative b-catenin/
TCF binding sites was not activated by TCF4-VP16 (Fig. 4c
and Supporting Information Fig. S6). Single-site point muta-
tions showed that only three putative b-catenin/TCF binding
sites contributed signiﬁcantly to TCF4-VP16 transcriptional
activity (sites #3, #4 and #7; Fig. 4b and d), whereas mutation
of the remaining motifs (sites #1, #2, #5 and #6) had no
effect (data not shown). Finally, a triple mutant targeting
these three sites revealed an additive inhibitory effect on
TCF4-VP16-mediated transcription, and some lingering
activity that suggests the possibility of additional regulatory
elements or residual activity of mutated sites (Fig. 4b and d).
During transcription, enhancer sequences are brought into
close proximity to the TSS, so that transcription factors bind-
ing to these regions can interact with the basal transcriptional
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machinery. We cloned the enhancer sequence described
above into pGL4.23 in both forward and reverse orientations
(Fig. 5a), and showed that TCF4-VP16 could stimulate lucif-
erase activity from both constructs with a potency compara-
ble to that of the DKK1 promoter, and even slightly stronger
in the reverse orientation (Fig. 5b). Therefore, we generated
single-point mutations in each of the three putative b-cate-
nin/TCF binding sites of the reverse-orientated enhancer, and
showed that mutations in site A completely abolished TCF4-
VP16-mediated transcription, while mutations in sites B and
C were totally innocuous (Fig. 5c). In summary, our data
suggest that b-catenin/TCF complexes induce transcription
Figure 2. Wnt3A induces the expression of Plakophilin-2 in CCD-18Co human colon myofibroblasts. (a) RT-qPCR analysis showing the upre-
gulation of PKP2 mRNA by Wnt3A. Results are shown as fold over control at the indicated times and are means6S.D. of three independent
biological samples, each one determined in triplicate (n.s., non-significant; *** p0.001). (b) Western blot analysis of Plakophilin-2 upre-
gulation by Wnt3A in a time course experiment. b-Actin was used as a loading control. Fold increases over vehicle-treated controls are indi-
cated. A representative experiment is shown. (c) The Wnt/b-catenin pathway/tankyrase inhibitor XAV-939 reduces Wnt3A-dependent
Plakophilin-2 upregulation. Cells were pre-treated for 4 hr with either 1 mM XAV-939 (1) or vehicle (–) and then stimulated with Wnt3A (1)
for 24 hr. b-Actin was used as a loading control. A representative experiment is shown. Bar plot represents means6S.D. of four indepen-
dent experiments (n.s., non-significant; ** p0.01). (d) Non-canonical Wnt5A cannot induce Plakophilin-2 accumulation. Myofibroblasts
were stimulated with either Wnt3A, Wnt5A or both for 24 hr, and Plakophilin-2 expression was analysed by Western blot. b-Actin was used
as a loading control. A representative experiment is shown. Bar plot represents means6S.D. of four independent experiments (n.s., non-
significant; ** p0.01). (e) RT-qPCR analysis of the expression of PKP family members in response to Wnt3A stimulation. CCD-18Co human
colon myofibroblasts were treated with either Wnt3A (1) or vehicle (–) for 24 hr. Results are shown as fold over control and are means6
S.D. of three independent biological samples, each one determined in triplicate (n.s., non-significant; *** p0.001).
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of the PKP2 gene through at least 3 binding sites in the pro-
moter region and one binding site in an enhancer region
located 20 kb upstream from the TSS (Fig. 5d).
Plakophilin-2 interferes with b-catenin/TCF transcriptional
activity
Next, we aimed to address the functional effects that an
increase in PKP2 gene expression triggered by Wnt3A in NF
and CAF might have on b-catenin/TCF transcriptional activ-
ity. To this end, we used the synthetic pTOPFLASH and
pFOPFLASH plasmids, which contain three copies of either a
wild-type or a mutant b-catenin/TCF binding consensus
sequence upstream of a minimal c-FOS promoter and the
Fireﬂy luciferase gene, which have been extensively used to
study b-catenin/TCF transcriptional activity.19 Transient
expression of Plakophilin-2 in HEK-293T cells impaired
activation of the pTOPFLASH reporter by wild-type b-cate-
nin (Fig. 6a). This effect was speciﬁc, since transcriptional
activation of the Notch pathway reporter 4xwtCBF1Luc by
ICND was unaffected by Plakophilin-2 (Fig. 6b), and activa-
tion of the NF-jB reporter NF3 by p65 was potentiated,
rather than inhibited, by Plakophilin-2 (Fig. 6c), as previ-
ously described.32 Remarkably, the inhibitory effect of
Plakophilin-2 on b-catenin/TCF-mediated transcription was
also conﬁrmed using the DKK1 promoter construct (Fig.
6d). This effect was not due to a decrease in b-catenin pro-
tein level, since this remained unaffected by Plakophin-2
expression (Fig. 6e). Altogether, these data show an inhibi-
tory effect of Plakophilin-2 on b-catenin-responsive
promoters.
Figure 3. Wnt3A induces PKP2/Plakophilin-2 expression in normal fibroblasts (NF) and in cancer-associated fibroblasts (CAF). NF and CAF
were obtained from CRC patients as described in the Materials and Methods and treated with either Wnt3A (1) or vehicle (–) for 24 hr.
Total RNA and protein was purified and PKP2/Plakophilin-2 mRNA and protein levels were analysed by RT-qPCR (a) and western blot (b),
respectively. Results in (a) are shown as fold over the NF control and are means6S.D. of three independent biological samples, each one
determined in triplicate (**p0.01; *** p0.001). b-Actin was used as a loading control in (b) and fold increases over vehicle-treated
controls are indicated.
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Discussion
Pericryptal stromal cells are essential for the maintenance of
colon tissue homeostasis, and also play an important role in
CRC progression. Wnt/b-catenin signalling is essential in
both these processes. Although the source and distribution of
Wnt proteins in the intestine is still a matter of debate, stro-
mal ﬁbroblasts are thought to be a major source of Wnts.33,34
Here we show that human colon myoﬁbroblasts are highly
responsive to Wnt3A, which causes a profound change in
their gene expression proﬁle leading to the up and downregu-
lation of a large set of genes. Therefore, Wnt factors can act
on epithelial cells at the bottom of the colon crypt but also
on pericryptal ﬁbroblasts that harbour functional Wnt recep-
tors and possibly other stromal cell types. The fact that
inhibitors of the Wnt/b-catenin pathway such as DKK2,
NKD1 and 2, or APCDD1 are among the strongest Wnt3A-
induced genes in colon myoﬁbroblasts could unveil a mecha-
nism to limit the actions of Wnt signalling on these cells or
perhaps to protect them from the effects of these factors that
are required for stem and proliferating cells at the bottom of
the crypt, but could be deleterious for the surrounding ﬁbro-
blasts. We cannot rule out the effect that secreted Wnt pro-
teins may have on other stromal cell types in healthy and
tumoural tissue, which warrants further investigation.
We compared the list of genes regulated by Wnt3A in
human colon myoﬁbroblasts with the gene sets representing
the biological functions enriched in the expression patterns
associated to each of the four consensus molecular subtypes
in colorectal cancer (CMS 1–4).8 The pattern of expression of
Wnt3A-treated myoﬁbroblasts clusterises closest to the
molecular subtype CMS2 (Supporting Information Fig. S7A),
which is characterized by WNT and MYC pathway activa-
tion.8 Therefore, although myoﬁbroblasts are stromal cells,
their molecular signature in response to Wnt3A is closest to
that of CMS2 instead of CMS4, despite the latter is character-
ized by a high stromal component. We also found a signiﬁ-
cant enrichment of TCF7L2/TCF-4 binding sites identiﬁed in
LS174T colon cancer cells35 in genes up and downregulated
Figure 4. The human PKP2 gene promoter is activated by b-catenin/TCF. (a) Actinomycin D (ACTD) blocks Wnt3A-induced accumulation of
PKP2 mRNA. CCD-18Co cells were pre-treated for 1 hr with either 5 mg/ml ACTD or vehicle and then stimulated with Wnt3A for 8 hr. Total
RNA was purified and PKP2 mRNA levels were analysed by RT-qPCR. Results are shown as fold over control and are means6S.D. of three
independent biological samples, each one determined in triplicate (n.s., nonsignificant; *** p0.001). (b) Diagram of the PKP2 promoter
constructs used in this study showing the location of the putative wild-type (50-CTTTG[A/T][A/T]-30, white boxes) or mutant (50-CTTTGGC-30,
X-crossed white boxes) b-catenin/TCF binding sites. (c) HEK-293T cells were co-transfected with the indicated PKP2 promoter constructs
together with TCF4-VP16 (1; a constitutively active form of TCF-4) or an empty vector (–). The b-catenin/TCF responsive DKK1 promoter was
used as a positive control. A Renilla luciferase plasmid (pRL-TK) was used as an internal control. Cells were lysed 48 hr after transfection
and Firefly and Renilla luciferase activities were measured. Values were normalized to those of Renilla. Error bars represent S.D.
(***p0.001). (d) HEK-293T cells were co-transfected with the indicated PKP2 promoter wild-type or mutant constructs together with TCF4-
VP16 (1) or an empty vector (–) and the experiment was performed as in (c). Error bars represent S.D. (*p0.05; ** p0.01; ***
p0.001).
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by Wnt3A in CCD-18Co myoﬁbroblasts (Supporting Infor-
mation Fig. S7B), which suggests that in spite of their differ-
ent linages there is a set of genes regulated by Wnt proteins
in both cell types. GSEA analysis also showed an enrichment
(almost signiﬁcant) of genes upregulated by Wnt3A in
NIH3T336 (FDR q-val5 0.08; FWER p-val5 0.10; Supporting
Information Fig. S7C) and dermal ﬁbroblasts37 (FDR q-
val5 0.08; FWER p-val5 0.18; Supporting Information Fig.
S7D) among genes induced by Wnt3A in CCD-18Co cells.
Likewise, genes downregulated by Wnt3A in CCD-18Co
myoﬁbroblasts were signiﬁcantly enriched in genes repressed
by Wnt3A in NIH3T336 (FDR q-val5 0.003; FWER p-
val5 0.002; Supporting Information Fig. S7E) which suggests
some conservation among genes regulated by Wnt3A in
ﬁbroblasts.
One of the genes that were most strongly upregulated by
Wnt3A was PKP2, which encodes the desmosomal protein
Plakophilin-2. Although this protein is best-known as a com-
ponent of epithelial cell desmosomes, it is also involved in
other types of adhesion structures, including composite junc-
tions (area compositae) in cardiomyocytes and a very speciﬁc
class of Plakophilin-2-containing adherens junctions (coniunc-
tiones adhaerentes) present in mesenchymally derived cells
with high proliferative activity.38 Moreover, Plakophilin-2
seems to have additional functions that are unrelated to
adhesion, since it has been consistently found inside the cell
Figure 5. An enhancer sequence located 20 kb upstream from the PKP2 transcription start site harbours a functional b-catenin/TCF respon-
sive element. (a) Diagram of the PKP2 enhancer constructs used in this study showing the location of the putative wild-type (50-CTTTG[A/
T][A/T]-30, white boxes) or mutant (50-CTTTGGC-30, X-crossed white boxes) b-catenin/TCF binding sites. (b) HEK-293T cells were co-
transfected with either the forward (–20666/–20091) or reverse (–20091/–20666) 575 bp PKP2 enhancer construct together with TCF4-
VP16 (1) or an empty vector (–). The DKK1 promoter was used as a positive control and pRL-TK as an internal control. Cells were lysed 48
hr after transfection and Firefly and Renilla luciferase activities were measured. Values were normalized to those of Renilla. Error bars repre-
sent S.D. (***p0.001). (c) HEK-293T cells were co-transfected with the indicated PKP2 enhancer wild-type or mutant constructs together
with TCF4-VP16 (1) or an empty vector (–) and the experiment was performed as in (b). Error bars represent S.D. (n.s., nonsignificant; ***
p0.001). (d) A diagram summarizing the human PKP2 gene regulatory sequences found in this study. White boxes represent functional
b-catenin/TCF binding sites.
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nucleus.39,40 We show here that Plakophilin-2 expression in
HEK-293T cells interferes with b-catenin/TCF transcriptional
activity, which implies that it might also be classiﬁed as a
Wnt inhibitor. Unfortunately, CCD-18Co cells are extremely
resistant to both transient transfection and lentiviral infec-
tion, so this has precluded Plakophilin-2 gain- and loss-of-
function studies in these cells.
Our results contrast with those of Chen and colleagues who
showed that Plakophilin-2 can bind b-catenin, and that expres-
sion of Plakophilin-2 in SW480 colon carcinoma cells had a
rather small but positive effect on b-catenin/TCF activity.41
This discrepancy suggests that the effect of Plakophilin-2 on b-
catenin-mediated transcription might be cell-type speciﬁc
or, perhaps, dependent on the status of the Wnt/b-catenin
pathway, since SW480 cells harbour a mutant APC protein and
have constitutively active Wnt signalling. In this regard, multi-
potent mesenchymal stromal cells and iPS cells from a patient
carrying a PKP2 gene mutation exhibited lower b-catenin/TCF
transcriptional activity than those of a healthy control.42 Inter-
estingly, another plakophilin family member, Plakophilin-1, has
been recently shown to be a critical mediator of Wnt signalling
in tooth development and ameloblast differentiation.43 This
hints at a close link between the PKP family and Wnt/b-catenin
signalling.
Our data show that PKP2 is regulated by b-catenin
through several response elements in the promoter and
enhancer regions of the gene. Sequence analysis of the puta-
tive b-catenin/TCF binding sites showed that the integrity of
Figure 6. Plakophilin-2 antagonizes b-catenin/TCF transcriptional activity. (a) HEK-293T cells were transfected with reporter plasmids (pTOP-
FLASH or pFOPFLASH) to evaluate the transcriptional activity of the Wnt/b-catenin pathway, together with an expression vector for b-catenin
(1) and in the presence or absence of an expression plasmid for Plakophilin-2. pRL-TK was used as an internal control. Cells were lysed 48
hr after transfection and Firefly and Renilla luciferase activities were measured. Values were normalized to those of Renilla, related to those
of the mutant pFOPFLASH construct, and represented as fold over control. Error bars represent S.D. (***p0.001). (b) HEK-293T cells were
transfected with reporter plasmids (4xwtCBF1Luc or 4xmtCBF1Luc) to evaluate the transcriptional activity of the Notch pathway, together
with an expression vector for IntraCellular Notch Domain (ICND, 1) and in the presence or absence of an expression plasmid for
Plakophilin-2. The experiment was performed as in (a). (c) HEK-293T cells were transfected with a reporter plasmid (NF3) to evaluate the
transcriptional activity of the NF-jB pathway, together with an expression vector for p65 (1) and in the presence or absence of an expres-
sion plasmid for Plakophilin-2. Samples were processed as in (a), values were normalized to those of Renilla, and represented as fold over
control. Error bars represent S.D. (*p0.05). (d) HEK-293T cells were transfected with the b-catenin/TCF responsive DKK1 promoter,
together with an expression vector for b-catenin (1) and in the presence or absence of an expression plasmid for Plakophilin-2. The experi-
ment was performed as in (a) and values are represented as fold over control. Error bars represent S.D. (***p0.001). (e) b-catenin protein
levels are not affected by Plakophilin-2 expression. Extracts from the experiment in (d) were analysed by Western blot to rule out the possi-
bility that the effects of Plakophilin-2 on b-catenin/TCF-dependent transcription were due to changes in b-catenin levels as a consequence
of Plakofilin-2 expression.
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the core sequence 50-CCTTTG(A/T)(A/T)-30 was essential for
functionality. Alterations in the ﬁrst 50 cytidine (sites #3 and
#7 in the promoter) still rendered a partially functional bind-
ing site, but changes affecting one of the 30 adenosines/thy-
midines (sites #1, #2, #5 and #6 in the promoter and sites B
and C in the enhancer region) rendered non-functional ele-
ments. ChIP-seq data obtained from UCSC Genome Browser
conﬁrmed that these sites are functional in vivo, and there-
fore that the PKP2 gene is a bona ﬁde Wnt target gene.
There is growing evidence of the involvement of
Plakophilin-2 and other plakophilins and desmosomal pro-
teins in cancer.44 Plakophilin-2 is widely expressed in carci-
nomas45,46 and in some of them its expression is associated
with invasive and metastatic behaviour.47,48 Recently,
Plakophilin-2 has been shown to promote tumour develop-
ment by binding the epidermal growth factor receptor
(EGFR) and enhancing its ligand-dependent and independent
activity.32 In spite of these data, further research is necessary
to clarify the role of Plakophilin-2 in different types of can-
cer. Classically, colorectal carcinoma cells have been thought
to be refractory to extracellular Wnt factors, since most of
them carry intracellular mutations (APC, CTNNB1/b-catenin
and AXIN1) that result in constitutive activation of the path-
way. However, it has been proposed recently that they can
respond to exogenous and autocrine Wnt ligands that further
activate the Wnt/b-catenin signalling pathway.49 In addition,
Wnt factors may exert some of their effects on CRC by tar-
geting CAF. Nevertheless, we found that PKP2 expression is
upregulated by Wnt3A in both normal and cancer-associated
ﬁbroblasts of different origins. This suggests that the gene is
not speciﬁcally induced in CAF, but is a general Wnt target
in ﬁbroblasts.
Plakophilin-2 is the only plakophilin expressed in the
heart and is essential for cell-cell adhesion in cardiomyo-
cytes.50,51 Actually, PKP2 mutations are the leading cause
of arrhythmogenic right ventricular cardiomyopathy
(ARVC):52,53 a major cause of sudden cardiac death. There-
fore, further studies should determine whether PKP2 is also a
Wnt target in the heart and, if so, evaluate the relevance of
its Wnt-regulated expression.
In summary, we show here that the PKP2 gene encoding
Plakophilin-2 is a novel Wnt/b-catenin target that could
function as a feedback inhibitor of b-catenin/TCF transcrip-
tional activity in colonic ﬁbroblasts, and perhaps in other cell
types. This is highly relevant, due to increasing evidence sug-
gesting the involvement of Plakophilin-2 in cancer and other
pathologies, and the key role of Wnt/b-catenin signalling in
colorectal carcinogenesis.
Acknowledgements
We thank Keith Brennan and Manuel Fresno for reagents and Lucille Banham
for her valuable assistance in the preparation of the English manuscript. This
work was supported by the Spanish Ministerio de Economıa y Competitividad
and the European Regional Development Fund (Fondos FEDER) (SAF2013–
43468-R, and SAF2014–53819-R), the Agencia Estatal de Investigacion-Fondos
FEDER (SAF2016–76377-R, AEI/FEDER, UE), the Comunidad de Madrid
(S2010/BMD-2344 Colomics2), the Instituto de Salud Carlos III–Fondos
FEDER (RD12/0036/0021, and CIBERONC-CB16/12/00273) and the Nuclear
Receptors Network (Nurcamein, SAF2015–71878-REDT).
REFERENCES
1. Torre LA, Bray F, Siegel RL, et al. Global cancer
statistics. CA Cancer J Clin 2015; 65:87–108.
2. Torre LA, Siegel RL, Ward EM, et al. Global can-
cer incidence and mortality rates and trends–an
update. Cancer Epidemiol Biomarkers Prev 2016;
25:16–27.
3. Fearon ER, Vogelstein B. A genetic model for
colorectal tumorigenesis. Cell 1990; 61:759–67.
4. Fearon ER. Molecular genetics of colorectal can-
cer. Annu Rev Pathol 2011;6:479–507.
5. Clevers H, Nusse R. Wnt/b-catenin signaling and
disease. Cell 2012; 149:1192–205.
6. Pietras K, Ostman A. Hallmarks of cancer: inter-
actions with the tumor stroma. Exp Cell Res
2010;316:1324–31.
7. Medema JP, Vermeulen L. Microenvironmental
regulation of stem cells in intestinal homeostasis
and cancer. Nature 2011; 474:318–26.
8. Guinney J, Dienstmann R, Wang X, et al. The
consensus molecular subtypes of colorectal can-
cer. Nat Med 2015; 21:1350–6.
9. Becht E, de Reynie`s A, Giraldo NA, et al.
Immune and Stromal Classiﬁcation of Colorectal
Cancer Is Associated with Molecular Subtypes
and Relevant for Precision Immunotherapy. Clin
Cancer Res 2016; 22:4057–66.
10. Isella C, Terrasi A, Bellomo SE, et al. Stromal
contribution to the colorectal cancer transcrip-
tome. Nat Genet 2015; 47:312–9.
11. Calon A, Lonardo E, Berenguer-Llergo A, et al.
Stromal gene expression deﬁnes poor-prognosis
subtypes in colorectal cancer. Nat Genet 2015; 47:
320–9.
12. Bass-Zubek AE, Godsel LM, Delmar M, et al. Pla-
kophilins: multifunctional scaffolds for adhesion
and signaling. Curr Opin Cell Biol 2009; 21:708–
16.
13. Herrera M, Islam AB, Herrera A, et al. Func-
tional heterogeneity of cancer-associated ﬁbro-
blasts from human colon tumors shows speciﬁc
prognostic gene expression signature. Clin Cancer
Res 2013; 19:5914–26.
14. Ferrer-Mayorga G, Gomez-Lopez G, Barbachano
A, Fernandez-Barral A, Pe~na C, Pisano DG,
Cantero R, Rojo F, Mu~noz A, Larriba MJ. Vita-
min D receptor expression and associated gene
signature in tumour stromal ﬁbroblasts predict
clinical outcome in colorectal cancer. Gut 2016;
gutjnl-2015–310977.
15. Kim D, Pertea G, Trapnell C, et al. TopHat2:
accurate alignment of transcriptomes in the pres-
ence of insertions, deletions and gene fusions.
Genome Biol 2013; 14:R36
16. Cunningham F, Amode MR, Barrell D, et al.
Ensembl 2015. Nucleic Acids Res 2015; 43:D662–
9.
17. Anders S, Pyl PT, Huber W. HTSeq–a Python
framework to work with high-throughput
sequencing data. Bioinformatics 2015; 31:
166–9.
18. Robinson MD, McCarthy DJ, Smyth GK. EdgeR:
a Bioconductor package for differential expression
analysis of digital gene expression data. Bioinfor-
matics 2010; 26:139–40.
19. Korinek V, Barker N, Morin PJ, et al. Constitu-
tive transcriptional activation by a b-catenin-Tcf
complex in APC-/- colon carcinoma. Science
1997; 275:1784–7.
20. Hsieh JJ, Henkel T, Salmon P, et al. Truncated
mammalian Notch1 activates CBF1/RBPJk-rep-
resed genes by a mechanism resembling that of
Epstein-Barrvirus EBNA2. Mol Cell Biol 1996; 16:
952–9.
21. Solanas G, Porta-de-la-Riva M, Agustı C, et al.
E-cadherin controls beta-catenin and NF-kappaB
transcriptional activity in mesenchymal
gene expression. J Cell Sci 2008; 121:
2224–34.
22. Gonzalez-Sancho JM, Aguilera O, Garcıa JM,
et al. The Wnt antagonist DICKKOPF-1 gene is a
downstream target of b-catenin/TCF and is
downregulated in human colon cancer. Oncogene
2005; 24:1098–103.
23. Navarro D, Agra N, Pesta~na A, et al. The EWS/
FLI1 oncogenic protein inhibits expression of the
Wnt inhibitor DICKKOPF-1 gene and antago-
nizes beta-catenin/TCF-mediated transcription.
Carcinogenesis 2010; 31:394–401.
24. Coiras M, Lopez-Huertas MR, Mateos E, et al.
Caspase-3-mediated cleavage of p65/RelA results
in a carboxy-terminal fragment that inhibits IjBa
and enhances HIV-1 replication in human T
lymphocytes. Retrovirology 2008; 5:109
M
ol
ec
ul
ar
C
an
ce
r
B
io
lo
gy
12 PKP2 is a novel Wnt/b-catenin target gene in fibroblasts
Int. J. Cancer: 00, 00–00 (2017) VC 2017 The Authors International Journal of Cancer published by John Wiley & Sons Ltd on behalf of UICC
25. Valentich JD, Popov V, Saada JI, Powell DW.
Phenotypic characterization of an intestinal sube-
pithelial myoﬁbroblast cell line. Am J Physiol
1997; 272:C1513–24.
26. Lyndsey S, Langhans SA. Crosstalk of oncogenic
signaling pathways during epithelial-mesenchymal
transition. Front Oncol 2014; 4:358
27. Pedersen EA, Menon R, Bailey KM, et al. Activa-
tion of Wnt/beta-catenin in Ewing sarcoma cells
antagonizes EWS/ETS function and promotes
phenotypic transition to more metastatic cell
states. Cancer Res 2016; 76:5040–53.
28. Kent WJ, Sugnet CW, Furey TS, et al. The
human Genome Browser at UCSC. Genome Res
2002; 12:996–1006.
29. ENCODE Project Consortium. An integrated
encyclopedia of DNA elements in the human
genome. Nature 2012; 489:57–74.
30. Niida A, Hiroko T, Kasai M, et al. DKK1, a nega-
tive regulator of Wnt signaling, is a target of the
beta-catenin/TCF pathway. Oncogene 2004; 23:
8520–6.
31. Chamorro M, Schwartz DR, Vonica A, et al.
FGF-20 and DKK1 are transcriptional targets of
beta-catenin and FGF-20 is implicated in cancer
and development. Embo J 2005; 24:
73–84.
32. Arimoto K, Burkart C, Yan M, et al. Plakophilin-
2 promotes tumor development by enhancing
ligand-dependent and -independent epidermal
growth factor receptor dimerization and activa-
tion. Mol Cell Biol 2014; 34:3843–54.
33. Kabiri Z, Greicius G, Madan B, et al. Stroma pro-
vides an intestinal stem cell niche in the absence
of epithelial Wnts. Development 2014; 141:2206–
15.
34. Gregorieff A, Wrana JL. Seeing is believing: Wnt3
localization in the gut epithelium. Cell Res 2016;
26:515–6.
35. Hatzis P, van der Flier LG, van Driel MA, et al.
Genome-wide pattern of TCF7L2/TCF4
chromatin occupancy in colorectal cancer cells.
Mol Cell Biol 2008; 28:2732–44.
36. Chen S, McLean S, Carter DE, et al. The gene
expression proﬁle induced by Wnt 3a in NIH
3T3 ﬁbroblasts. J Cell Commun Signal 2007; 1:
175–83.
37. Sobel K, Tham M, Stark HJ, et al. Wnt-3a-acti-
vated human ﬁbroblasts promote human kerati-
nocyte proliferation and matrix destruction. Int J
Cancer 2015; 136:2786–98.
38. Franke WW, Rickelt S, Barth M, et al. The junc-
tions that don’t ﬁt the scheme: special symmetri-
cal cell-cell junctions of their own kind. Cell
Tissue Res 2009; 338:1–17.
39. Mertens C, Kuhn C, Franke WW. Plakophilins
2a and 2b: constitutive proteins of dual location
in the karyoplasm and the desmosomal plaque.
J Cell Biol 1996; 135:1009–25.
40. Mertens C, Hofmann I, Wang Z, et al. Nuclear
particles containing RNA polymerase III com-
plexes associated with the junctional plaque pro-
tein plakophilin 2. Proc Natl Acad Sci USA 2001;
98:7795–800.
41. Chen X, Bonne S, Hatzfeld M, et al. Protein
binding and functional characterization of plako-
philin 2. Evidence for its diverse roles in desmo-
somes and b-catenin signaling. J Biol Chem 2002;
277:10512–22.
42. Khudiakov AA, Kostina DA, Kostareva AA, et al.
The effect of plakophilin-2 gene mutations on the
activity of canonical Wnt signaling. Cell Tiss Biol
2016; 10:106–13.
43. Miyazaki K, Yoshizaki K, Arai C, et al. Plakophi-
lin-1, a novel Wnt signaling regulator, is critical
for tooth development and ameloblast differentia-
tion. PLOS One 2016; 11:e0152206
44. Huber O, Petersen I. 150th Anniversary Series:
Desmosomes and the Hallmarks of Cancer. Cell
Commun Adhes 2015; 22:15–28.
45. Mertens C, Kuhn C, Moll R, et al. Desmosomal
plakophilin 2 as a differentiation marker in
normal and malignant tissues. Differentiation
1999; 64:277–90.
46. Schwarz J, Ayim A, Schmidt A, et al. Differential
expression of desmosomal plakophilins in various
types of carcinomas: correlation with cell type
and differentiation. Hum Pathol 2006; 37:613–22.
47. Papagerakis S, Shabana AH, Depondt J, et al.
Immunohistochemical localization of plakophilins
(PKP1, PKP2, PKP3, and p0071) in primary oro-
pharyngeal tumors: correlation with clinical
parameters. Hum Pathol 2003; 34:565–72.
48. Takahashi H, Nakatsuji H, Takahashi M, et al.
Up-regulation of plakophilin-2 and down-
regulation of plakophilin-3 are correlated with
invasiveness in bladder cancer. Urology 2012; 79:
240.e1–8.
49. Voloshanenko O, Erdmann G, Dubash TD, et al.
Wnt secretion is required to maintain high levels
of Wnt activity in colon cancer cells. Nat Comms
2013;4:2610,. doi: 10.1038/ncomms3610.
50. Grossmann KS, Grund C, Huelsken J, et al.
Requirement of plakophilin 2 for heart morpho-
genesis and cardiac junction formation. J Cell
Biol 2004; 167:149–60.
51. Pieperhoff S, Schumacher H, Franke WW. The
area composita of adhering junctions connecting
heart muscle cells of vertebrates. V. The impor-
tance of plakophilin-2 demonstrated by small
interference RNA-mediated knockdown in cul-
tured rat cardiomyocytes. Eur J Cell Biol 2008;
87:399–411.
52. Gerull B, Heuser A, Wichter T, et al. Muta-
tions in the desmosomal protein plakophilin-2
are common in arrhythmogenic right ventricu-
lar cardiomyopathy. Nat Genet 2004; 36:
1162–4.
53. Van Tintelen JP, Entius MM, Bhuiyan ZA, et al.
Plakophilin-2 mutations are the major determi-
nant of familial arrhythmogenic right ventricular
dysplasia/cardiomyopathy. Circulation 2006; 113:
1650–8.
M
ol
ec
ul
ar
C
an
ce
r
B
io
lo
gy
Niell et al. 13
Int. J. Cancer: 00, 00–00 (2017) VC 2017 The Authors International Journal of Cancer published by John Wiley & Sons Ltd on behalf of UICC
